Patents by Inventor Christoph ERKEL

Christoph ERKEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
    Patent number: 11939397
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 26, 2024
    Assignee: Novartis AG
    Inventors: Michael Didonato, Christoph Erkel, Anna Galkin, Scott Glaser, Klaus Felix Hartlepp, Yong Jia, Alexandra Kraus, Christian Cho-Hua Lee, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler
  • IL-1 Receptor Accessory Protein Inhibitors and Uses Thereof
    Publication number: 20220411517
    Abstract: The present disclosure provides novel antibodies and fragments thereof targeting IL-1RAcP. Use of IL-1RAcP inhibitors are also provided herein.
    Type: Application
    Filed: May 20, 2022
    Publication date: December 29, 2022
    Inventors: Birgitte Ursø, Waseem Sajid, Paola Lovato, Heidi Westh Bagger, Christoph Erkel, Petra Nussbaumer, Simon Schuster
  • ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
    Publication number: 20220348651
    Abstract: Provided herein are methods of treating cancer using an antibody or antigen-binding fragments thereof that specifically bind to human ENTPD2 protein, and compositions comprising these antibodies or antigen-binding fragments for use in the treatment of cancer. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: September 17, 2020
    Publication date: November 3, 2022
    Inventors: Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
  • COMBINATION THERAPY WITH ENTPD2 AND CD73 ANTIBODIES
    Publication number: 20220340685
    Abstract: Provided herein are combinations comprising an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to ENTPD2 (e.g., human ENTPD2 protein), and an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to CD73 (e.g., human CD73 protein), and methods of using these combinations.
    Type: Application
    Filed: September 17, 2020
    Publication date: October 27, 2022
    Inventors: Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
  • ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
    Publication number: 20210155713
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: May 29, 2019
    Publication date: May 27, 2021
    Inventors: Michael DIDONATO, Christoph ERKEL, Anna Galkin, Scott GLASER, Klaus Felix HARTLEPP, Yong JIA, Alexandra KRAUS, Christian Cho-Hua LEE, Sarah Michelle RUE, Jian SHI, Xenia Karola WEZLER